Incyte Q4 total revenue $1.51B (+28% YoY); FY 2025 net product revenue beat guidance

INCYTE CORP

2025-FY EPS reported $6.41 revenue$5,141,242,000

Q4 total revenue $1.51B (+28% YoY); net product revenue $1.22B (+20%). FY 2025 net product revenue $4.35B, above $4.23-4.32B guidance.
GAAP diluted EPS Q4 $1.46, FY $6.41; non-GAAP diluted EPS Q4 $1.80, FY $6.80.
2026 total net product revenue guidance $4.77-4.94B, including Jakafi $3.22-3.27B and Opzelura $750-790M.
Pipeline: positive frontMIND Phase 3 for tafasitamab in DLBCL; Jakafi XR filing submitted, decision mid-2026; INCA033989 registrational plans; ruxolitinib cream PN paused.
Cash $3.6B; entered option agreement with Prelude Therapeutics for JAK2V617F inhibitor program ($100M option exercise).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.